Last Week aTyr Pharma, Inc. (NASDAQ:LIFE) Ratings

May 17, 2018 - By Alicia Butler

aTyr Pharma, Inc. (NASDAQ:LIFE) Corporate Logo

aTyr Pharma, Inc. (NASDAQ:LIFE) Ratings Coverage

A total of 3 analysts rate aTyr Pharma (NASDAQ:LIFE) as follows: 0 “Buy”, 0 “Hold” and 3 “Sell”. Тherefore 0 are bullish. (NASDAQ:LIFE) has 3 ratings reports on May 17, 2018 according to StockzIntelligence. On Wednesday, February 14 the rating was downgraded by J.P. Morgan to “Sell”. On Wednesday, February 14 JP Morgan downgraded the shares of LIFE in report to “Underweight” rating. On Tuesday, May 15 the stock of aTyr Pharma, Inc. (NASDAQ:LIFE) has “Sell” rating given by Citigroup. Listed here are aTyr Pharma, Inc. (NASDAQ:LIFE) PTs and latest ratings.

15/05/2018 Broker: Citigroup Rating: Sell New Target: $1.0000 Downgrade
14/02/2018 Broker: J.P. Morgan Rating: Sell Downgrade
14/02/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Underweight Downgrade

Ticker’s shares touched $0.95 during the last trading session after 11.20% change.aTyr Pharma, Inc. has 1.04M shares volume, 681.58% up from normal. LIFE is downtrending and has moved 19.01% since May 17, 2017. The stock underperformed the S&P 500 by 30.56%.

aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of Physiocrine therapeutics for patients suffering from severe and rare diseases.The firm is valued at $28.17 million. The firm develops Resolaris, which is in Phase Ib/II clinical trials for treating patients with facioscapulohumeral muscular dystrophy , early onset FSHD, and limb-girdle muscular dystrophy, as well as under evaluation to treat Duchenne muscular dystrophy.Currently it has negative earnings. The Company’s discovery program includes Stalaris for treating interstitial lung disease with an immune component; and preclinical research program comprises Project ORCA to treat therapeutic applications of Physiocrines.

For more aTyr Pharma, Inc. (NASDAQ:LIFE) news released briefly go to: Benzinga.com, Seekingalpha.com, Nasdaq.com, Nasdaq.com or Benzinga.com. The titles are as follows: “Benzinga’s Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings” released on May 16, 2018, “Premarket analyst action – healthcare” on May 15, 2018, “Mid-Afternoon Market Update: Precipio Surges Following Strong Preliminary Q1 Results; aTyr Pharma Shares Slide” with a publish date: May 14, 2018, “aTyr Pharma Presents Poster on Preclinical Data from ATYR1923 Program at American Thoracic Society 2018 …” and the last “Benzinga Pro’s 5 Stocks To Watch Today” with publication date: May 17, 2018.

aTyr Pharma, Inc. (NASDAQ:LIFE) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.